Can subcutaneous amniotic membrane use help prevent keloids at the incision site?

Applied beneath the skin at the closure site, amniotic membrane may reduce inflammation and modulate fibroblast activity, two key drivers of keloid formation. This biologic function mirrors AM’s natural role in the body, making its use during cesarean delivery a homologous application under FDA guidelines. The biologic consistency, regulatory framing, and growing body of clinical evidence support AM’s role in wound modulation and scar prevention. Similar biologic principles may extend to other surgical contexts where keloid risk is elevated, including breast augmentation and revision procedures.

Is keloid revision typically covered by insurance?

Coverage varies. Procedures deemed cosmetic—such as post-augmentation or elective scar revision—are often excluded. Many practices offer cash-pay options for patients seeking improved aesthetic outcomes or recurrence prevention.

What size amniotic grafts are used in keloid procedures?

Graft size depends on the location and technique. For topical post excision use, such as ear or breast augmentation, ophthalmic-sized grafts (5mm, 8mm) may be sufficient. For subcutaneous applications, such as cesarean keloid revision, larger grafts, e.g., 8x10 or larger, may be required to cover the excision site and support healing.

Does Medicare reimburse for AM in keloid procedures?

No. HCPCS code V2790 (amniotic membrane for surgical reconstruction) is no longer reimbursed separately. In facility settings, AM is considered part of the procedure. In office-based settings, reimbursement may vary. Cash-pay models are often used for cosmetic revisions.

Allogeneic Solutions Keloids Top 1920x880

Anti-Fibrotic Properties

Q: Is amniotic membrane used in keloid revision procedures?

Amniotic membrane allografts are increasingly used post-excision to support healing and reduce recurrence. Their anti-fibrotic and anti-inflammatory properties make them ideal adjuncts in keloid management, especially for high-visibility areas like the ear, breast, and abdomen.

Keloids represent a challenging clinical condition characterized by excessive collagen deposition and persistent fibroblast activation, leading to raised, firm scars that extend beyond the original wound boundaries. Traditional treatments often yield suboptimal results with high recurrence rates. Emerging evidence suggests that amniotic membrane (AM) allografts, possess properties that can modulate fibrotic responses, offering a promising avenue for keloid management.

Shared Fibrotic Pathways in Corneal and Dermal Fibroblasts

Both corneal fibroblasts (keratocytes) and dermal fibroblasts involved in keloid formation share common fibrotic pathways, notably the TGF-β signaling cascade. In the cornea, AM has been shown to suppress TGF-β isoforms and their receptors, inhibiting myofibroblast differentiation and reducing scarring. Similarly, in dermal tissues, AM's anti-fibrotic effects have been observed, suggesting a potential crossover in therapeutic applications.

Keloid Revision

The anti-fibrotic and anti-inflammatory properties of amniotic membrane allografts support keloid revision, particularly for high-demand procedures like breast augmentation and cesarean scar management.

Mechanisms of Action

1. TGF-β Modulation: AM contains factors that downregulate TGF-β signaling, a key driver in fibrotic processes. By inhibiting this pathway, AM reduces fibroblast proliferation and collagen synthesis.

2. Anti-Inflammatory Properties: The AM matrix harbors anti-inflammatory cytokines that mitigate local inflammation, a contributor to keloid pathogenesis.

3. Extracellular Matrix Remodeling: AM promotes balanced collagen and proteoglycan synthesis, aiding in the restoration of normal tissue architecture and preventing excessive scar formation.

Clinical Implications

The application of AM in ocular surgeries has demonstrated its efficacy in reducing scarring and promoting regenerative healing. Translating these findings to dermatological contexts, particularly in the management of keloids, is supported by the shared fibrotic mechanisms. Preliminary studies have shown that application of AM post-keloid excision can lead to improved healing outcomes and reduced recurrence rates.

Conclusion

The anti-fibrotic and anti-inflammatory properties of amniotic membrane allografts, present a compelling case for their use in keloid management. By targeting the underlying fibrotic pathways common to both corneal and dermal fibroblasts, amniotic membrane allografts offer a biologically active solution to a condition often resistant to conventional therapies.

Start a Conversation

Clinical Considerations

A: A keloid is an overgrowth of scar tissue that extends beyond the original wound boundary, often appearing raised and firm.

A: Applied beneath the skin at the closure site, amniotic membrane may reduce inflammation and modulate fibroblast activity, two key drivers of keloid formation.

A: Cesarean incisions often occur in areas of tension and repeated stress, which can trigger abnormal scar formation in predisposed individuals.

A: Amniotic membrane contains growth factors and anti-inflammatory proteins that regulate fibroblast activity, reduce scar tissue deposition, and promote balanced healing.

A: Procedures such as breast augmentation, revision surgeries, and dermatologic excisions may benefit from biologic adjuncts like amniotic membrane to reduce keloid risk.

A: Amniotic membrane placement is well‑defined in ophthalmology, with CPT codes 65778, 65779, and 65780. These ocular codes are referenced here for informational purposes only. In dermatologic and keloid revision contexts, AM use is typically bundled within the primary excision or revision procedure rather than billed separately. Coding will vary by payer policy and surgical technique. Always consult current CPT guidance and payer‑specific edits.

Note: Graft sizes referenced are based on published clinical use cases and manufacturer specifications. Selection may vary by surgical technique, wound geometry, and provider preference. Always consult current literature and product instructions for use (IFU) for guidance.

1. Tseng, S. C. G., Li, D. Q., & Ma, X. (1999). Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. Journal of Cellular Physiology, 179(3), 325–

2. Eslahi, N., Nejad, Z. M., Rezaei-Tavirani, M., & Akbari, S. (2025). Amniotic membrane transplantation for wound healing, tissue engineering, and regenerative medicine. Stem Cell Reviews and Reports, 21(2), 345–359. https://doi.org/10.1007/s12015-025-10892-x

3. Bhatti, M., Adwan, A., Kamal, R., Singh, K., & Anand, S. (2024). Human amniotic membrane modulates collagen production and enhances wound healing. Scientific Reports, 14(1), 2789. https://doi.org/10.1038/s41598-024-64364-2

4. Davenport, B., Tatro, E., Phillips, H., & Yamin, F. (2019). Amniotic and umbilical cord particulate in the management of keloid and hypertrophic scars. Journal of Wound Care, 28(7), 456–462. https://doi.org/10.12968/jowc.2019.28.7.456A nice paragraph